Literature DB >> 3697976

Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.

A Rahman, D Carmichael, M Harris, J K Roh.   

Abstract

The comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes was evaluated in rats at a dose of 6 mg/kg i.v. Doxorubicin was entrapped in cardiolipin liposomes by using 11.2 mumol of drug, 5.6 mumol of cardiolipin, 28.5 mumol of phosphatidylcholine, 19.5 mumol of cholesterol, and 11.1 mumol of stearylamine. The peak plasma concentration with free doxorubicin at 5 min was 1.7 micrograms/ml which was reduced to 0.3 micrograms/ml by 1 h. With cardiolipin liposomes, the peak plasma concentration of doxorubicin achieved at 5 min was 20.9 micrograms/ml. The plasma levels of doxorubicin decreased gradually and by 1 h the drug concentration in plasma was 10 micrograms/ml. The plasma levels of free doxorubicin and doxorubicin entrapped in liposomes were fitted to a 3-compartment computer model. The terminal half-life with free doxorubicin in plasma was 17.3 h whereas it was 69.3 h with drug entrapped in liposomes. The area under the plasma concentration curve with liposomal doxorubicin was 81.4 micrograms X h X ml-1 compared to 1.95 micrograms X h X ml-1 observed with free doxorubicin. The steady state volume of distribution with free doxorubicin was about 23-fold higher than liposomal doxorubicin. The terminal half-life with free doxorubicin in cardiac tissue was 17.9 h compared to 12.6 h with drug encapsulated in liposomes. The terminal half-lives in liver and spleen following administration of liposomal doxorubicin were 15- and 2.3-fold higher, respectively, compared to free drug; furthermore, the concentration X time values of liposomal doxorubicin in liver were 26-fold higher and in spleen 6-fold higher than the free drug. Free doxorubicin and doxorubicin entrapped in liposomes demonstrated 17 and 20% excretion in bile of the injected dose, respectively, in rats. The present studies demonstrate that liposomal encapsulation of doxorubicin significantly alters its pharmacokinetics in plasma and tissues compared to free drug.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3697976

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin.

Authors:  K M Wasan; R E Morton
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

2.  Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study.

Authors:  Muna Aryal; Natalia Vykhodtseva; Yong-Zhi Zhang; Nathan McDannold
Journal:  J Control Release       Date:  2015-02-24       Impact factor: 9.776

3.  The TGF-β pathway mediates doxorubicin effects on cardiac endothelial cells.

Authors:  Zuyue Sun; Jill Schriewer; Mingxin Tang; Jerry Marlin; Frederick Taylor; Ralph V Shohet; Eugene A Konorev
Journal:  J Mol Cell Cardiol       Date:  2015-12-11       Impact factor: 5.000

4.  Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.

Authors:  Mandana Namdar; Gisela Perez; Lang Ngo; Paul A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-29       Impact factor: 11.205

5.  Pharmacokinetics and antitumor effect of doxorubicin carried by stealth and remote loading proliposome.

Authors:  J P Wang; Y Maitani; K Takayama; T Nagai
Journal:  Pharm Res       Date:  2000-07       Impact factor: 4.200

6.  Bicontinuous cubic liquid crystalline nanoparticles for oral delivery of Doxorubicin: implications on bioavailability, therapeutic efficacy, and cardiotoxicity.

Authors:  Nitin K Swarnakar; Kaushik Thanki; Sanyog Jain
Journal:  Pharm Res       Date:  2013-11-12       Impact factor: 4.200

7.  The architecture and biological performance of drug-loaded LbL nanoparticles.

Authors:  Stephen W Morton; Zhiyong Poon; Paula T Hammond
Journal:  Biomaterials       Date:  2013-04-22       Impact factor: 12.479

8.  Multifunctional superparamagnetic iron oxide nanoparticles for combined chemotherapy and hyperthermia cancer treatment.

Authors:  Christopher A Quinto; Priya Mohindra; Sheng Tong; Gang Bao
Journal:  Nanoscale       Date:  2015-07-08       Impact factor: 7.790

9.  Oscillatory dynamics in a model of vascular tumour growth--implications for chemotherapy.

Authors:  I J Stamper; M R Owen; P K Maini; H M Byrne
Journal:  Biol Direct       Date:  2010-04-20       Impact factor: 4.540

10.  Thermal and pH Sensitive Multifunctional Polymer Nanoparticles for Cancer Imaging and Therapy.

Authors:  Tingjun Lei; Romila Manchanda; Alicia Fernandez-Fernandez; Yen-Chih Huang; Douglas Wright; Anthony J McGoron
Journal:  RSC Adv       Date:  2014-01-01       Impact factor: 3.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.